


Form PTO/SB/08A				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	Herewith
				First Named Inventor	Bernhard KEPPLER
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet 1 of 1	Attorney Docket Number	8182-25US (PA32424US)	1626 <i>Robert J. Hickey</i>		

U.S. PATENT DOCUMENTS					
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document		Date of Publication of Cited Document MM-YYYY
	Number	Kind Code (if known)			
<i>12</i>	4,843,069		KELLER et al.		06-1989

FOREIGN PATENT DOCUMENTS					
Exr Initials	Foreign Patent Document			Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY
	Country Code	Number	Kind Code (if known)		
<i>12</i>	WO	97/36595	A2	Richard-Wagner-Strasse	10-1997 *X
				*Abstract Only	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.				
<i>12</i>	F.T. GARZON et al., "Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats", <i>Cancer Chemother Pharmacol</i> , pp. 347-349, (1987)				
<i>12</i>	B.K. Keppler et al., "New Ruthenium Complexes for the Treatment of Cancer", <i>Progress in Clinical Biochemistry and Medicine</i> , Vol. 10, pp. 41-69, (1989)				
<i>12</i>	H. DEPENBROCK et al., "Preclinical Activity of Trans-indazolium [Tetrachlorobisindazoleruthenate (III)] (NSC 666158; IndCR; KP 1019) Against Tumour Colony-forming Units and Haematopoietic Progenitor Cells", <i>European Journal of Cancer</i> , Vol. 33, No. 14, pp. 2404-2410, (1997)				
<i>12</i>	A. GALEANO et al., "Antitumor Activity of Some Ruthenium Derivatives in Human Colon Cancer Cell Lines in vitro", <i>Arzneim.-Forsch./Drug Res.</i> , 42, Vol. 1, No. 6, pp. 821-824, (1992)				
<i>12</i>	F. KRATZ et al., "Protein-Binding Properties Of Two Antitumour Ru(III) Complexes To Human Apotransferrin And Apolactoferrin", <i>Metal-Based Drugs</i> , Vol. 1, Nos. 2-3, pp. 169-173 (1994)				
<i>12</i>	F. KRATZ et al., "Comparison Of The Antiproliferative Activity Of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin And Transferrin-Bound Forms In A Human Colon Cancer Cell Line", <i>Metal-Based Drugs</i> , Vol. 3, No. 1, pp. 15-23, (1996)				
<i>12</i>	Y.N. VASHISHT GOPAL et al., "Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium", <i>J. Biosci.</i> , Vol. 26, No. 2, pp. 271-276, (2001)				
<i>12</i>	ERNST D. KREUSER et al., "Synergistic Antitumor Interactions Between Newly Synthesized Ruthenium Complexes and Cytokines in Human Colon Carcinoma Cell Lines", <i>Seminars in Oncology</i> , Vol. 19, No. 2 Suppl 3, pp. 73-81, (1992)				
<i>12</i>	S. PACOR et al., "Antitumor action of mer-trichlorobis (dimethylsulphoxide) aminoruthenium (III) (BBR2382) in mice bearing lewis lung carcinoma", <i>Metal Ions in Biology and Medicine</i> , pp. 482-484, (1990)				

Examiner Signature	<i>Carl Jr.</i>	Date Considered	12/14/05
--------------------	-----------------	-----------------	----------



<p>Form 100-08A FEDERAL BUREAU OF INVESTIGATION INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>	<p><i>Complete if Known</i></p>		
	Application Number	10/627,519	
	Filing Date	July 25, 2003	
	First Named Inventor	Bernhard KEPPLER	
	Group Art Unit	Not Yet Assigned	
	Examiner Name	Not Yet Assigned	
Attorney Docket Number		1626 Robert Shidell	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	Ti
25	F. KRALIK et al., "Complex compounds of trivalent ruthenium with pyrazol and imidazol", <i>Collection Czechoslov. Chem. Commun.</i> , Vol. 26, pp. 1298-1304, (1961).	
	B.K. KEPPLER et al., "Synthesis Molecular Structure, and Tumor-Inhibiting Properties of Imidazolium trans-Bis(imidazole)tetrachlororuthenate(III) and Its Methyl-Substituted Derivatives", <i>Inorg. Chem.</i> , Vol. 26, pp. 4366-4370, (1987).	
	MARTIN R. BERGER et al., "Efficacy of New Ruthenium Complexes against Chemically Induced Autochthonous Colorectal Carcinoma in Rats", <i>Anticancer Res.</i> , Vol. 9, pp. 761-766, (1989).	
	E. ALESSIO et al., "Carbonyl Derivatives of Chloride-Dimethyl Sulfoxide-Ruthenium(II) Complexes: Systhesis, Structural Characterization, and Reactivity of $\text{Ru}(\text{CO})_x(\text{DMSO})_{4-x}\text{C}_1$ Complexes ($x=1-3$)", <i>Inorg. Chem.</i> , Vol. 34, pp. 4722-4734, (1995).	
	WOLFGANG PETI et al., "Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion trans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt", <i>Eur. J. Inorg. Chem.</i> , pp. 1551-1555, (1999).	
	B.K. KEPPLER et al., "New Tumor-Inhibiting Metal Complexes. Chemistry and Antitumor Properties", <i>Met-Based Drugs</i> , Vol. 1, Nos. 2-3, pp. 145-150, (1994).	
	MATTHIAS H. SEELIG et al., "Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats", <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 118, No. 3, pp. 195-200, (1992).	
15	MICHAEL J. CLARK, "The Potential of Ruthenium in Anticancer Pharmaceuticals", <i>American Chemical Society Symp. Ser.</i> , pp. 157-180 (1980).	

Examiner Signature		Date Considered	12/4/2015
--------------------	---	-----------------	-----------